Literature DB >> 21967873

[Mexican clinical practice guidelines of immunotherapy 2011].

Désirée Larenas-Linnemann1, José Antonio Ortega-Martell, Blanca Del Río-Navarro, Noel Rodríguez-Pérez, Alfredo Arias-Cruz, Alan Estrada, Martín Becerril-Ángeles, Dino R Pietropaolo-Cienfuegos, Maria de Jesús Ambriz-Moreno, Carlos Báez-Loyola, Enna Cossío-Ochoa, Sandra Nora González-Díaz, Emilia María Hidalgo-Castro, Rosa Elena Huerta-Hernández, Alejandra Macías-Weinmann, Joel Oyoqui-Flores, Héctor Stone-Aguilar, Marisol Belinda Treviño-Salinas, María Del Carmen Zárate-Hernández.   

Abstract

BACKGROUND: Several international guidelines on immunotherapy exist, but they only apply partially in Mexico. The Mexican guideline of immunotherapy dates from 1998.
OBJECTIVES: To establish clinical recommendations and suggestions for Allergy residents and specialists for skin testing and allergen immunotherapy based on evidence and Mexican expert opinion, according to the GRADE system.
METHODS: The guidelines were developed following the methodology of a guideline for clinical practice starting with the formulation of clinical questions, in the context of Mexican environmental conditions and morbidity, with the participation of allergists from all regions of the country. External validation was obtained. Its development followed three steps: 1. formulation of 24 clinical questions. 2. Search for consensus on the answers among members of the Regional chapters of both Mexican Colleges of Allergists (CMICA and COMPEDIA) during regional meetings. 3. Literature search for articles related to the questions and grading of its quality according to GRADE.
RESULTS: Based on the regional consensus, 116 articles and the safety, patient acceptance/ comfort and cost clinical recommendations and suggestions were developed on basic aspects of skin testing, subcutaneous and sublingual immunotherapy (patient preparation, vial preparation and application schedules) and the treatment of eventual adverse reactions.
CONCLUSIONS: A clinical guideline was developed respecting particular methodology, validated by CMICA and COMPEDIA for its implementation among Mexican allergists. Several aspects deserve further study to improve scientific evidence. KEYWORDS: Allergen immunotherapy, subcutaneous immunotherapy, sublingual immunotherapy, skin testing, allergy diagnosis, rhinitis, asthma, atopic dermatitis, house dust mite, pollens, anaphylaxis, adrenaline, Mexico.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21967873

Source DB:  PubMed          Journal:  Rev Alerg Mex        ISSN: 0002-5151


  4 in total

Review 1.  Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines.

Authors:  Désirée Larenas-Linnemann; Noel Rodríguez-Pérez; Jorge A Luna-Pech; Mónica Rodríguez-González; María Virginia Blandón-Vijil; Blanca E Del-Río-Navarro; María Del Carmen Costa-Domínguez; Elsy Maureen Navarrete-Rodríguez; Carlos Macouzet-Sánchez; José Antonio Ortega-Martell; César Fireth Pozo-Beltrán; Alan Estrada-Cardona; Alfredo Arias-Cruz; Karen Guadalupe Rodríguez Galván; Herson Brito-Díaz; María Del Rosario Canseco-Raymundo; Enrique Emanuel Castelán-Chávez; Alberto José Escalante-Domínguez; José Luis Gálvez-Romero; Javier Gómez-Vera; Sandra Nora González-Díaz; María Gracia Belinda Guerrero-Núñez; Dante Daniel Hernández-Colín; Alejandra Macías-Weinmann; David Alejandro Mendoza-Hernández; Néstor Alejandro Meneses-Sánchez; María Dolores Mogica-Martínez; Carol Vivian Moncayo-Coello; Juan Manuel Montiel-Herrera; Patricia María O'Farril-Romanillos; Ernesto Onuma-Takane; Margarita Ortega-Cisneros; Lorena Rangel-Garza; Héctor Stone-Aguilar; Carlos Torres-Lozano; Edna Venegas-Montoya; Guillermo Wakida-Kusunoki; Armando Partida-Gaytán; Aída Inés López-García; Ana Paola Macías-Robles; María de Jesús Ambriz-Moreno; Amyra Ali Azamar-Jácome; Claudia Yusdivia Beltrán-De Paz; Chrystopherson Caballero-López; Juan Carlos Fernández de Córdova-Aguirre; José Roberto Fernández-Soto; José Santos Lozano-Sáenz; José Joel Oyoqui-Flores; Roberto Efrain Osorio-Escamilla; Fernando Ramírez-Jiménez; Daniela Rivero-Yeverino; Eric Martínez Infante; Miguel Alejandro Medina-Ávalos
Journal:  World Allergy Organ J       Date:  2020-08-21       Impact factor: 4.084

2.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update.

Authors:  Giorgio Walter Canonica; Linda Cox; Ruby Pawankar; Carlos E Baena-Cagnani; Michael Blaiss; Sergio Bonini; Jean Bousquet; Moises Calderón; Enrico Compalati; Stephen R Durham; Roy Gerth van Wijk; Désirée Larenas-Linnemann; Harold Nelson; Giovanni Passalacqua; Oliver Pfaar; Nelson Rosário; Dermot Ryan; Lanny Rosenwasser; Peter Schmid-Grendelmeier; Gianenrico Senna; Erkka Valovirta; Hugo Van Bever; Pakit Vichyanond; Ulrich Wahn; Osman Yusuf
Journal:  World Allergy Organ J       Date:  2014-03-28       Impact factor: 4.084

3.  Allergen sensitization linked to climate and age, not to intermittent-persistent rhinitis in a cross-sectional cohort study in the (sub)tropics.

Authors:  Désirée Larenas-Linnemann; Alexandra Michels; Hanna Dinger; Kijawasch Shah-Hosseini; Ralph Mösges; Alfredo Arias-Cruz; Marichuy Ambriz-Moreno; Martín Bedolla Barajas; Ruth Cerino Javier; María de la Luz Cid Del Prado; Manuel Alejandro Cruz Moreno; Roberto García Almaráz; Cecilia Y García-Cobas; Daniel A Garcia Imperial; Rosa Garcia Muñoz; Dante Hernández-Colín; Francisco J Linares-Zapien; Jorge A Luna-Pech; Juan J Matta-Campos; Norma Martinez Jiménez; Miguel A Medina-Ávalos; Alejandra Medina Hernández; Alberto Monteverde Maldonado; Doris N López; Luis J Pizano Nazara; Emmanuel Ramirez Sanchez; José D Ramos-López; Noel Rodríguez-Pérez; Pablo G Rodríguez-Ortiz
Journal:  Clin Transl Allergy       Date:  2014-06-04       Impact factor: 5.871

Review 4.  Contraindications to immunotherapy: a global approach.

Authors:  C Pitsios; M Tsoumani; M B Bilò; G J Sturm; P Rodríguez Del Río; R Gawlik; F Ruëff; G Paraskevopoulos; E Valovirta; O Pfaar; M A Calderón; P Demoly
Journal:  Clin Transl Allergy       Date:  2019-09-11       Impact factor: 5.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.